News Releases

All Releases
View Summary Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
Apr 23, 2014
PDF 6.2 KB Add to Briefcase
View Summary Johnson & Johnson Reports 2014 First-Quarter Results:
Apr 15, 2014
PDF 48.4 KB Add to Briefcase
View Summary Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress 2014 of the European Association for the Study of the Liver (EASL)
Apr 12, 2014
PDF 124.5 KB Add to Briefcase
View Summary Supplemental New Drug Application for IMBRUVICATM (ibrutinib) Submitted to the U.S. FDA
Apr 8, 2014
PDF 19.9 KB Add to Briefcase
View Summary Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C
Apr 2, 2014
PDF 11.0 KB Add to Briefcase
View Summary Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy
Apr 1, 2014
PDF 17.5 KB Add to Briefcase
View Summary Johnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics
Mar 31, 2014
 
View Summary Janssen Expands the EXPLORER Global Cardiovascular Research Program with Three New Studies Evaluating XARELTO® in Patients at Risk for Venous Thromboembolism
Mar 31, 2014
PDF 27.0 KB Add to Briefcase
View Summary Janssen receives positive CHMP opinion for simeprevir in the treatment of adults with chronic hepatitis C in the European Union
Mar 24, 2014
PDF 15.5 KB Add to Briefcase
View Summary Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment of Moderate to Severe Plaque Psoriasis
Mar 24, 2014
PDF 15.1 KB Add to Briefcase
View Summary Johnson & Johnson to Webcast Annual Meeting of Shareholders
Mar 21, 2014
PDF 6.7 KB Add to Briefcase
View Summary Siltuximab Receives CHMP Positive Opinion for use in the Treatment of Multicentric Castleman's Disease, a very Rare Blood Disorder
Mar 21, 2014
PDF 15.0 KB Add to Briefcase
View Summary Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse
Mar 20, 2014
PDF 18.4 KB Add to Briefcase
View Summary Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 11, 2014
PDF 7.0 KB Add to Briefcase
View Summary SIRTURO® (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-Drug Resistant Tuberculosis
Mar 6, 2014
PDF 16.4 KB Add to Briefcase
View Summary Biosense Webster Receives FDA Approval for First Catheter Ablation Therapy in the U.S. to Feature Direct Contact Force Technology for Treatment of Atrial Fibrillation
Feb 25, 2014
PDF 95.8 KB Add to Briefcase
View Summary Johnson & Johnson to Participate in 2014 Cowen 34th Annual Health Care Conference
Feb 25, 2014
PDF 5.7 KB Add to Briefcase
View Summary Cordis Corporation Receives CE Mark for RENLANE™ Renal Denervation System to Treat Resistant Hypertension
Feb 21, 2014
PDF 9.5 KB Add to Briefcase
View Summary VOKANAMET (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1]
Feb 21, 2014
PDF 15.5 KB Add to Briefcase
View Summary Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy
Feb 21, 2014
PDF 25.5 KB Add to Briefcase

= add release to Briefcase